AbbVie Q2 2026 Earnings Report

AbbVie EPS Results

• Actual EPS: N/A
• Consensus EPS: $3.79
• Beat/Miss: N/A
• One Year Ago EPS: N/A

AbbVie Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $16.77 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

AbbVie Announcement Details

• Quarter: Q2 2026
• Date: 7/31/2026
• Time: Before Market Opens
• Conference Call Date: Friday, July 31, 2026
• Conference Call Time: 9:00AM ET

AbbVie (NYSE:ABBV) is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health. Historically, the company has been best known for Humira (adalimumab), a leading therapy for several autoimmune diseases. AbbVie’s broader commercial and development lineup has included oncology medicines such as Imbruvica and Venclexta, as well as newer immunology treatments and specialty products. The 2020 acquisition of Allergan expanded AbbVie’s offerings into aesthetics and eye care, adding well-known products such as Botox to its portfolio and diversifying its revenue and clinical focus.

AbbVie markets its products globally and maintains research, development and commercial operations in numerous regions around the world. The company invests heavily in clinical development and collaborates with academic institutions, biotechnology companies and other partners to advance its pipeline. AbbVie is led by Chairman and Chief Executive Officer Richard A. Gonzalez, and its strategic priorities emphasize innovation in specialty medicines, lifecycle management of key assets and expansion into adjacent therapeutic and commercial areas through acquisition and partnership.